Here are six new drug shortages and discontinuations, according to drug supply databases from the FDA and the American Society of Health-System Pharmacists.
Editor’s note: The drugs listed are in alphabetical order.
- Aminolevulinic acid powder for oral solution: NX Development Corp’s Gleolan, used to help visualize high-grade gliomas during brain tumor surgery, is in shortage. The manufacturer did not provide a reason for delay and no presentations are currently available.
- Bumetanide tablet: Upsher-Smith Laboratories has discontinued five presentations of bumetanide tablets in 0.5 mg, 1 mg and 2 mg doses, which are used as diuretics to treat fluid retention associated with heart failure, liver disease and kidney disorders.
- Doxazosin extended release oral tablets: Mylan has reported a shortage of Cardura XL, a treatment for high blood pressure and symptoms of benign prostatic hyperplasia. The 4 mg and 8 mg presentations were recalled in December due to impurity issues found during stability testing.
- Doxycycline hyclate tablet: Teva Pharmaceuticals has discontinued two 100 mg tablet presentations of doxycycline Hyclate, an antibiotic used to treat bacterial infections including respiratory tract infections, acne and certain sexually transmitted diseases.
- Drospirenone; ethinyl estradiol tablet: Teva Pharmaceuticals has discontinued Ocella, a combination oral contraceptive used to prevent pregnancy. No resupply date was announced.
- Heparin sodium injection: Hospira, a Pfizer company, has discontinued its heparin sodium injection (5,000 USP units/mL), which is used as an anticoagulant to prevent and treat blood clots. The discontinuation was due to a manufacturing decision.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.